CN103732612B - Notch通路信号转导抑制剂化合物 - Google Patents

Notch通路信号转导抑制剂化合物 Download PDF

Info

Publication number
CN103732612B
CN103732612B CN201280037471.9A CN201280037471A CN103732612B CN 103732612 B CN103732612 B CN 103732612B CN 201280037471 A CN201280037471 A CN 201280037471A CN 103732612 B CN103732612 B CN 103732612B
Authority
CN
China
Prior art keywords
cancer
leukemia
pharmaceutically acceptable
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280037471.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103732612A (zh
Inventor
P.A.希普斯金
G.A.斯蒂芬森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103732612A publication Critical patent/CN103732612A/zh
Application granted granted Critical
Publication of CN103732612B publication Critical patent/CN103732612B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280037471.9A 2011-07-27 2012-07-18 Notch通路信号转导抑制剂化合物 Expired - Fee Related CN103732612B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US61/512016 2011-07-27
US201161560486P 2011-11-16 2011-11-16
US61/560486 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (2)

Publication Number Publication Date
CN103732612A CN103732612A (zh) 2014-04-16
CN103732612B true CN103732612B (zh) 2015-09-23

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280037471.9A Expired - Fee Related CN103732612B (zh) 2011-07-27 2012-07-18 Notch通路信号转导抑制剂化合物

Country Status (36)

Country Link
US (1) US8569286B2 (cg-RX-API-DMAC10.html)
EP (1) EP2736920B1 (cg-RX-API-DMAC10.html)
JP (1) JP6027110B2 (cg-RX-API-DMAC10.html)
KR (1) KR101578309B1 (cg-RX-API-DMAC10.html)
CN (1) CN103732612B (cg-RX-API-DMAC10.html)
AP (1) AP4080A (cg-RX-API-DMAC10.html)
AR (1) AR087107A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012287251B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014001600B1 (cg-RX-API-DMAC10.html)
CA (1) CA2841178C (cg-RX-API-DMAC10.html)
CL (1) CL2014000175A1 (cg-RX-API-DMAC10.html)
CO (1) CO6862159A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140036A (cg-RX-API-DMAC10.html)
CY (1) CY1116645T1 (cg-RX-API-DMAC10.html)
DK (1) DK2736920T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2014000011A (cg-RX-API-DMAC10.html)
EA (1) EA023044B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP14013179A (cg-RX-API-DMAC10.html)
ES (1) ES2544937T3 (cg-RX-API-DMAC10.html)
GT (1) GT201400012A (cg-RX-API-DMAC10.html)
HR (1) HRP20150771T1 (cg-RX-API-DMAC10.html)
HU (1) HUE027534T2 (cg-RX-API-DMAC10.html)
IL (1) IL229988A (cg-RX-API-DMAC10.html)
JO (1) JO3148B1 (cg-RX-API-DMAC10.html)
MA (1) MA35611B1 (cg-RX-API-DMAC10.html)
ME (1) ME02171B (cg-RX-API-DMAC10.html)
MX (1) MX356536B (cg-RX-API-DMAC10.html)
MY (1) MY184303A (cg-RX-API-DMAC10.html)
PE (1) PE20141061A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500215B1 (cg-RX-API-DMAC10.html)
PL (1) PL2736920T3 (cg-RX-API-DMAC10.html)
PT (1) PT2736920E (cg-RX-API-DMAC10.html)
RS (1) RS54135B1 (cg-RX-API-DMAC10.html)
SI (1) SI2736920T1 (cg-RX-API-DMAC10.html)
TW (1) TWI568730B (cg-RX-API-DMAC10.html)
WO (1) WO2013016081A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX380779B (es) * 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
EP3458091B1 (en) * 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
JP2019526632A (ja) * 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018359907A1 (en) * 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
EP3790552A4 (en) * 2018-05-06 2022-06-15 Ayala Pharmaceuticals Inc. COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
BR112021006092A2 (pt) 2018-10-02 2021-07-20 Frequency Therapeutics, Inc. composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados
MX2021012258A (es) 2019-04-08 2022-01-04 Frequency Therapeutics Inc Combinacion de chir99021 y acido valproico para tratar la perdida auditiva.
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
CN100480248C (zh) 2003-02-04 2009-04-22 弗·哈夫曼-拉罗切有限公司 用作γ-分泌酶抑制剂的丙二酰胺衍生物
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
SI1673347T1 (sl) 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
WO2007110335A1 (en) 2006-03-27 2007-10-04 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
KR101150574B1 (ko) * 2007-02-02 2012-05-30 에프. 호프만-라 로슈 아게 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체
US20090181944A1 (en) 2008-01-11 2009-07-16 John Frederick Boylan Method for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
CN103732612A (zh) 2014-04-16
ES2544937T3 (es) 2015-09-07
PE20141061A1 (es) 2014-09-06
BR112014001600B1 (pt) 2022-09-13
HRP20150771T1 (hr) 2015-08-28
DOP2014000011A (es) 2014-07-31
US20130029972A1 (en) 2013-01-31
CA2841178C (en) 2016-12-20
DK2736920T3 (en) 2015-07-20
EP2736920B1 (en) 2015-07-01
ME02171B (me) 2015-10-20
EA201490161A1 (ru) 2014-04-30
PT2736920E (pt) 2015-09-16
TWI568730B (zh) 2017-02-01
US8569286B2 (en) 2013-10-29
HUE027534T2 (en) 2016-11-28
JO3148B1 (ar) 2017-09-20
JP6027110B2 (ja) 2016-11-16
BR112014001600A2 (pt) 2017-02-21
JP2014527042A (ja) 2014-10-09
CR20140036A (es) 2014-03-21
CO6862159A2 (es) 2014-02-10
KR20140026624A (ko) 2014-03-05
PL2736920T3 (pl) 2015-11-30
PH12014500215A1 (en) 2014-03-17
KR101578309B1 (ko) 2015-12-16
EP2736920A1 (en) 2014-06-04
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
AP2014007362A0 (en) 2014-01-31
TW201315732A (zh) 2013-04-16
AR087107A1 (es) 2014-02-12
SI2736920T1 (sl) 2015-08-31
AP4080A (en) 2017-03-29
AU2012287251A1 (en) 2014-01-30
WO2013016081A1 (en) 2013-01-31
PH12014500215B1 (en) 2018-09-07
MY184303A (en) 2021-03-31
NZ618891A (en) 2015-12-24
CL2014000175A1 (es) 2014-08-22
ECSP14013179A (es) 2014-03-31
GT201400012A (es) 2014-07-16
MX356536B (es) 2018-06-01
MA35611B1 (fr) 2014-11-01
IL229988A (en) 2017-07-31
HK1194086A1 (en) 2014-10-10
RS54135B1 (sr) 2015-12-31
CY1116645T1 (el) 2017-03-15
AU2012287251B2 (en) 2015-05-14
MX2014001084A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
DK2736920T3 (en) CONNECTION TO INHIBITION OF NOTCH SIGNAL ROAD
JP6412278B2 (ja) 平滑筋肉腫の標的治療
JP2025512920A (ja) ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製
WO2018228474A1 (zh) 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CN118684666A (zh) Kif18a抑制剂及其用途
EP4010343B1 (en) 7,8-dihydro-4h-pyrazolo[4,3-c]azepine-6-one compounds
NZ618891B2 (en) Notch pathway signaling inhibitor compound
HK1194086B (en) Notch pathway signaling inhibitor compound
WO2019170086A1 (zh) 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用
HK1251166B (en) Targeted treatment of leiomyosarcoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150923